2006-06-01
Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant
Publication
Publication
European Journal of Endocrinology , Volume 154 - Issue 6 p. 805- 806
We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant. The hepatic enzyme disturbances normalized after discontinuation of pegvisomant. After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis. Clinicians should be aware of this potential severe adverse drug reaction and therefore frequent control of hepatic enzymes is mandatory during treatment with pegvisomant.
Additional Metadata | |
---|---|
doi.org/10.1530/eje.1.02160, hdl.handle.net/1765/56070 | |
European Journal of Endocrinology | |
Organisation | Department of Internal Medicine |
Feenstra, J., van Aken, M., de Herder, W., Feelders, R., & van der Lely, A.-J. (2006). Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology, 154(6), 805–806. doi:10.1530/eje.1.02160 |